Inventor · disambiguated record
Jessica R. Kirshner
Also filed as: KIRSHNER JESSICA · KIRSHNER JESSICA R
29 granted patents·10 pending applications·290 citations·filing 2007–2025
96Inventor score
Top patents by PatentIndex Score
39 records- 0198US9302015B2Anti-PRLR antibodies and methods for killing PRLR-expressing cellsREGENERON PHARMA·Filed 2014·Granted Apr 5, 2016·82 cites·57 claims
- 0297US10772972B2Anti-STEAP2 antibody drug conjugates, and compositions and uses thereofREGENERON PHARMA·Filed 2017·Granted Sep 15, 2020·44 cites·41 claims
- 0397US10179819B2Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereofREGENERON PHARMA·Filed 2016·Granted Jan 15, 2019·25 cites·12 claims
- 0496US10738130B2Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereofREGENERON PHARMA·Filed 2017·Granted Aug 11, 2020·50 cites·49 claims
- 0595US11485793B2Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereofREGENERON PHARMA·Filed 2020·Granted Nov 1, 2022·4 cites·44 claims
- 0695US11155633B2Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereofREGENERON PHARMA·Filed 2018·Granted Oct 26, 2021·9 cites·24 claims
- 0794US11633501B2Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereofREGENERON PHARMA·Filed 2020·Granted Apr 25, 2023·3 cites·14 claims
- 0894US11384153B2Bispecific anti-BCMA x anti-CD3 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jul 12, 2022·16 cites·24 claims
- 0993US10941208B2Anti-MUC16 antibodiesREGENERON PHARMA·Filed 2017·Granted Mar 9, 2021·6 cites·2 claims
- 1093US10550193B2Methods and antibody compositions for tumor treatmentREGENERON PHARMA·Filed 2015·Granted Feb 4, 2020·8 cites·32 claims
- 1193US9475875B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2015·Granted Oct 25, 2016·14 cites·9 claims
- 1292US11905332B2Antigen-binding molecules that bind CD38 and/or CD28, and uses thereofREGENERON PHARMA·Filed 2021·Granted Feb 20, 2024·3 cites·43 claims
- 1391US10738124B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2018·Granted Aug 11, 2020·3 cites·27 claims
- 1490US10806780B2Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereofREGENERON PHARMA·Filed 2018·Granted Oct 20, 2020·4 cites·17 claims
- 1587US9545451B2Anti-PRLR antibodies and methods for killing PRLR-expressing cellsREGENERON PHARMA·Filed 2014·Granted Jan 17, 2017·6 cites·21 claims
- 1684US11559576B2Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereofREGENERON PHARMA·Filed 2020·Granted Jan 24, 2023·1 cites·23 claims
- 1784US9688764B2Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodiesREGENERON PHARMA·Filed 2016·Granted Jun 27, 2017·3 cites·47 claims
- 1883US2025064913A1Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1982US11434300B2Methods and antibody compositions for tumor treatmentREGENERON PHARMA·Filed 2019·Granted Sep 6, 2022·2 cites·20 claims
- 2082US10683354B2Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cellsREGENERON PHARMA·Filed 2018·Granted Jun 16, 2020·1 cites·26 claims
- 2182US10106616B2Antagonist antibodies to human prolactin receptor (PRLR)REGENERON PHARMA·Filed 2017·Granted Oct 23, 2018·2 cites·16 claims
- 2281US2025282891A1Anti-PSMA Antibodies, Bispecific Antigen-Binding Molecules that Bind PSMA and CD3, and Uses ThereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2380US12115216B2Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereofREGENERON PHARMA·Filed 2022·Granted Oct 15, 2024·0 cites·19 claims
- 2479US10925971B2Methods of treating PRLR positive breast cancerREGENERON PHARMA·Filed 2017·Granted Feb 23, 2021·1 cites·34 claims
- 2579US10662244B2Methods for tumor treatment using CD3XCD20 bispecific antibodyREGENERON PHARMA·Filed 2015·Granted May 26, 2020·2 cites·17 claims
- 2676US12344677B2Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereofREGENERON PHARMA·Filed 2021·Granted Jul 1, 2025·0 cites·28 claims
- 2775US12258412B2Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodiesREGENERON PHARMA·Filed 2022·Granted Mar 25, 2025·0 cites·20 claims
- 2875US10047160B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2016·Granted Aug 14, 2018·1 cites·13 claims
- 2974US2023220101A1Methods and Antibody Compositions for Tumor TreatmentREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3072US11608380B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2020·Granted Mar 21, 2023·0 cites·11 claims
- 3171US2024325445A1Chimeric Antigen Receptors with BCMA Specificity and Uses ThereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3270US2025043002A1BISPECIFIC PD-L1xCD28 ANTIBODIES AND METHODS OF USE THEREOFREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3370US2025042999A1Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulationREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3467US2025043017A1BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOFREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3565US12150959B2Chimeric antigen receptors with BCMA specificity and uses thereofREGENERON PHARMA·Filed 2019·Granted Nov 26, 2024·0 cites·25 claims
- 3660US12091460B2Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulationREGENERON PHARMA·Filed 2020·Granted Sep 17, 2024·0 cites·17 claims
- 3760US2024293566A1ANTI-EGFRvIII ANTIBODY DRUG CONJUGATES AND USES THEREOFREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3859US2009093538A1Method for treating cancerSYNTA PHARMACEUTICALS CORP·Filed 2007·Application pending·0 cites
- 3946US2020399372A1Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulationREGENERON PHARMA·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jessica R. Kirshner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →